- Home
- LOCL vs BOLD Comparison
LOCL vs BOLD Comparison
Compare LOCL & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LOCL | BOLD |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | 333 | N/A |
| Industry | Farming/Seeds/Milling | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 25.7M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | LOCL | BOLD |
|---|---|---|
| Price | $1.12 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 23.4K | ★ 64.6K |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.93 | N/A |
| Revenue Next Year | $82.62 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.98 | $0.96 |
| 52 Week High | $5.75 | $1.79 |
Technical Indicators
Market Signals| Indicator | LOCL | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 28.07 | 52.49 |
| Support Level | N/A | $1.15 |
| Resistance Level | $2.75 | $1.20 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 16.06 | 56.25 |
Price Performance
Historical ComparisonAbout LOCL Local Bounti Corporation
Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.